Perinatal and Reproductive Psychiatry Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Am J Obstet Gynecol. 2010 Feb;202(2):171.e1-171.e11. doi: 10.1016/j.ajog.2009.10.868. Epub 2009 Dec 24.
Menopause-associated insomnia is commonly associated with other symptoms (hot flashes, depression, anxiety). Given frequent symptom cooccurrence, therapies targeting sleep may provide an important approach to treatment during midlife.
Peri/postmenopausal women (40-65 years old) with sleep-onset and/or sleep-maintenance insomnia cooccurring with hot flashes and depressive and/or anxiety symptoms were randomized to eszopiclone 3 mg orally or placebo in a double-blinded, crossover 11 week trial. Changes in the Insomnia Severity Index (ISI) scale and secondary outcomes (diary-based sleep parameters, depression/anxiety, hot flashes, quality of life) were analyzed using repeated-measure linear models.
Of 59 women, 46 (78%) completed the study. Eszopiclone reduced ISI scores by 8.7 + or - 1.4 more points than placebo (P < .0001). Eszopiclone improved (P < .05) all sleep parameters, depressive symptoms, anxiety symptoms, quality of life, and nighttime but not daytime hot flashes.
Eszopiclone treats insomnia and cooccurring menopause-related symptoms. Our results provide evidence that hypnotic therapies may improve multiple domains of well-being during midlife.
与其他症状（热潮、抑郁、焦虑）相关的绝经相关失眠症很常见。鉴于频繁出现症状共病，针对睡眠的治疗方法可能是中年期间治疗的重要方法。
患有入睡和/或睡眠维持性失眠症，伴有热潮、抑郁和/或焦虑症状的围绝经期/绝经后妇女（40-65 岁）随机分为艾司佐匹克隆 3 毫克口服或安慰剂，在双盲、交叉 11 周试验中。使用重复测量线性模型分析了失眠严重程度指数（ISI）量表和次要结局（日记睡眠参数、抑郁/焦虑、热潮、生活质量）的变化。
在 59 名女性中，46 名（78%）完成了研究。与安慰剂相比，艾司佐匹克隆使 ISI 评分降低了 8.7±1.4 分（P<.0001）。艾司佐匹克隆改善了（P<.05）所有睡眠参数、抑郁症状、焦虑症状、生活质量以及夜间但不包括日间热潮。
艾司佐匹克隆治疗失眠症和同时发生的与绝经相关的症状。我们的结果提供了证据，表明催眠疗法可能会改善中年期间多个健康领域。
